Wordt geladen...
A phase II trial of abiraterone combined with dutasteride for men with metastatic castration-resistant prostate cancer
PURPOSE: Despite the efficacy of abiraterone, a CYP17A1 inhibitor, in metastatic castration-resistant prostate cancer (CRPC), nearly all patients develop resistance. The purpose of this phase II study was to evaluate mechanisms of resistance to more complete androgen synthesis inhibition with abirat...
Bewaard in:
| Gepubliceerd in: | Clin Cancer Res |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315609/ https://ncbi.nlm.nih.gov/pubmed/27683182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-0987 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|